146 related articles for article (PubMed ID: 32789809)
1. Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects.
Finck B; Tang H; Civoli F; Hodge J; O'Kelly H; Vexler V
Adv Ther; 2020 Oct; 37(10):4291-4307. PubMed ID: 32789809
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
[TBL] [Abstract][Full Text] [Related]
5. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies.
Civoli F; Finck B; Tang H; Hodge J; O'Kelly H; Vexler V
Adv Ther; 2022 Mar; 39(3):1230-1246. PubMed ID: 35034311
[TBL] [Abstract][Full Text] [Related]
8. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
Singh I; Patel A; Patel R; Jose V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.
Sveikata A; Gumbrevičius G; Seštakauskas K; Kregždytė R; Janulionis V; Fokas V
Medicina (Kaunas); 2014; 50(3):144-9. PubMed ID: 25323541
[TBL] [Abstract][Full Text] [Related]
11. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim.
Gattu S; Wang J; Bellon A; Schelcher C; Nakov R; Arani R
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1130-1141. PubMed ID: 34350732
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
Singh I; Attrey A; Garg A; Patel R; Jose V
Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
[TBL] [Abstract][Full Text] [Related]
17. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
Bellon A; Wang J; Skerjanec A; Velinova M; Dickerson D; Sabet A; Ngo L; O'Reilly T; Tomek C; Schussler S; Schier-Mumzhiu S; Gattu S; Koch SD; Schelcher C; Dobreva M; Boldea A; Nakov R; Otto GP
Br J Clin Pharmacol; 2020 Jun; 86(6):1139-1149. PubMed ID: 32022282
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg
Roth K; Lehnick D; Wessels H; Höfler J; Gastl B; Jankowsky R
Pharmacol Res Perspect; 2019 Oct; 7(5):e00503. PubMed ID: 31417680
[TBL] [Abstract][Full Text] [Related]
20. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv.
MacDonald K; McBride A; Alrawashdh N; Abraham I
J Med Econ; 2020 Dec; 23(12):1466-1476. PubMed ID: 33023360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
